Frequent upregulation of HER2 protein in hormone-receptor-positive HER2-negative breast cancer after short-term neoadjuvant endocrine therapy.

[1]  Amy R. Peck,et al.  NSG-Pro mouse model for uncovering resistance mechanisms and unique vulnerabilities in human luminal breast cancers , 2021, Science advances.

[2]  A. Degnim,et al.  Surgical Management of Axilla Following Neoadjuvant Endocrine Therapy , 2021, Annals of Surgical Oncology.

[3]  D. Murawa,et al.  Surgical Management of the Axilla in Clinically Node-Positive Breast Cancer Patients Converting to Clinical Node Negativity through Neoadjuvant Chemotherapy: Current Status, Knowledge Gaps, and Rationale for the EUBREAST-03 AXSANA Study , 2021, Cancers.

[4]  H. Rugo,et al.  Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. , 2020, Clinical breast cancer.

[5]  E. Mittendorf,et al.  Axillary Management After Neoadjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer , 2020, Annals of Surgical Oncology.

[6]  M. Morrow,et al.  How Effective is Neoadjuvant Endocrine Therapy (NET) in Downstaging the Axilla and Achieving Breast-Conserving Surgery? , 2020, Annals of Surgical Oncology.

[7]  A. Turnbull,et al.  Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumours , 2018, Breast Cancer Research.

[8]  B. Taylor,et al.  The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. , 2018, Cancer cell.

[9]  T. Nielsen,et al.  Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. , 2017, Seminars in cancer biology.

[10]  Adrian V. Lee,et al.  Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases , 2017, JAMA oncology.

[11]  J. Tyson,et al.  Endocrine resistance in breast cancer – An overview and update , 2015, Molecular and Cellular Endocrinology.

[12]  M. Ellis,et al.  Mechanisms of aromatase inhibitor resistance , 2015, Nature Reviews Cancer.

[13]  T. Nielsen,et al.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  Susanna M Cramb,et al.  The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality. , 2012, Cancer epidemiology.

[15]  Rachel Schiff,et al.  Mechanisms of endocrine resistance in breast cancer. , 2011, Annual review of medicine.

[16]  D. El-Ashry,et al.  ER Re-expression and Re-sensitization to Endocrine Therapies in ER-negative Breast Cancers , 2009, Journal of Mammary Gland Biology and Neoplasia.

[17]  Jingqin Luo,et al.  Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics , 2008, Journal of the National Cancer Institute.

[18]  A. Thor,et al.  Downregulation of erbB3 abrogates erbB2‐mediated tamoxifen resistance in breast cancer cells , 2007, International journal of cancer.

[19]  I. Bièche,et al.  Role of estrogen receptor α transcriptional coregulators in tamoxifen resistance in breast cancer , 2006 .

[20]  W. Carney,et al.  Serum HER‐2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy , 2005, Cancer.

[21]  R. Schiff,et al.  Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. , 2004, Journal of the National Cancer Institute.

[22]  M. Dowsett,et al.  Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. , 2001, Endocrine-related cancer.

[23]  R. Nicholson,et al.  Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. , 2001, Endocrine-related cancer.

[24]  A. Jemal,et al.  Global Cancer Statistics , 2011 .